Biotechnology Product Coverage, Coding, and Reimbursement Strategies, in Biotechnology Entrepreneurship

Robert Wanerman, a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, co-wrote a chapter titled "Biotechnology Product Coverage, Coding, and Reimbursement Strategies."

Following is an excerpt:

Bringing a new drug, biological, medical devices, or diagnostic to market is an arduous process that can take years, cost tens of millions of dollars, and requires compliance with multiple regulatory processes. ?...

Even at the early stage of development, overlooking the reimbursement processes that come into play after FDA or other national authority approval can mean the difference between ultimate success and failure. ?...

This chapter will explain these reimbursement processes. Although the challenges for each product may be different, understanding the mechanics of coverage, coding, and reimbursement is essential for identifying the issues and evaluating any potential options.